Moreover, the 36-month beta value for XENE is 1.21. Analysts have varying opinions on the stock, with 11 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for XENE is 73.30M and currently, short sellers hold a 4.90% of that float. On January 30, 2025, XENE’s average trading volume was 393.12K shares.
XENE) stock’s latest price update
The stock price of Xenon Pharmaceuticals Inc (NASDAQ: XENE) has surged by 0.37 when compared to previous closing price of 40.19, but the company has seen a 0.90% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-01-16 that Xenon Pharmaceuticals’ Azetukalner has good Phase 2 data for MDD using Kv7 potassium channels. This also gives it a good safety profile. The company has robust financials with a runway that should last into 2027 or more. So, I think it should have enough resources to take its late-stage pipeline to approval. Epilepsy and MDD have an attractive TAM of several billions of dollars in the US and abroad. XENE could tap into these niche markets over time.
XENE’s Market Performance
Xenon Pharmaceuticals Inc (XENE) has seen a 0.90% rise in stock performance for the week, with a 3.89% gain in the past month and a -3.35% plunge in the past quarter. The volatility ratio for the week is 3.43%, and the volatility levels for the past 30 days are at 3.53% for XENE. The simple moving average for the last 20 days is 1.59% for XENE stock, with a simple moving average of -0.13% for the last 200 days.
Analysts’ Opinion of XENE
Many brokerage firms have already submitted their reports for XENE stocks, with Raymond James repeating the rating for XENE by listing it as a “Outperform.” The predicted price for XENE in the upcoming period, according to Raymond James is $50 based on the research report published on October 10, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see XENE reach a price target of $53. The rating they have provided for XENE stocks is “Buy” according to the report published on October 01st, 2024.
Citigroup gave a rating of “Buy” to XENE, setting the target price at $62 in the report published on January 04th of the previous year.
XENE Trading at 0.29% from the 50-Day Moving Average
After a stumble in the market that brought XENE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.89% of loss for the given period.
Volatility was left at 3.53%, however, over the last 30 days, the volatility rate increased by 3.43%, as shares surge +4.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.81% lower at present.
During the last 5 trading sessions, XENE rose by +0.45%, which changed the moving average for the period of 200-days by -2.76% in comparison to the 20-day moving average, which settled at $39.70. In addition, Xenon Pharmaceuticals Inc saw 2.91% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XENE starting from MORTIMER IAN, who sale 22,468 shares at the price of $40.20 back on Jan 24 ’25. After this action, MORTIMER IAN now owns 31,302 shares of Xenon Pharmaceuticals Inc, valued at $903,214 using the latest closing price.
MORTIMER IAN, the PRESIDENT & CEO of Xenon Pharmaceuticals Inc, sale 16,315 shares at $40.50 during a trade that took place back on Jan 27 ’25, which means that MORTIMER IAN is holding 31,302 shares at $660,806 based on the most recent closing price.
Stock Fundamentals for XENE
Current profitability levels for the company are sitting at:
- -47.49 for the present operating margin
- 0.61 for the gross margin
The net margin for Xenon Pharmaceuticals Inc stands at -39.66. The total capital return value is set at -0.32. Equity return is now at value -29.75, with -28.32 for asset returns.
Based on Xenon Pharmaceuticals Inc (XENE), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -16.42. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -33.56.
Currently, EBITDA for the company is -210.51 million with net debt to EBITDA at 0.31. When we switch over and look at the enterprise to sales, we see a ratio of 554.78. The receivables turnover for the company is 5.74for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 22.21.
Conclusion
To wrap up, the performance of Xenon Pharmaceuticals Inc (XENE) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
